ClinicalTrials.gg
Sign In

Drug

Allogeneic Invariant Natural Killer T-cells agenT-797 clinical trials

Also written agenT-797.

studies test it
7
open now
3
in phase 3
0
first study started
2020

Keep track of what changes. Save the Allogeneic Invariant Natural Killer T-cells agenT-797 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Development codes

agenT-797
6

Studies by the year they started

7 studies that test it; most in 2026 (4)

Studies that test Allogeneic Invariant Natural Killer T-cells agenT-797, by start year
YearStudies
20201
20211
20241
20264

By phase

A phase 1/2 study counts in both.

Phase 1
3
Phase 2
4

What it is tested for

Each study’s main condition, where its own words name it.

Respiratory Distress Syndrome
2
Esophageal Neoplasms
1
Multiple Myeloma
1
Leukemia, Myeloid, Acute
1
Colorectal Neoplasms
1
Pneumonia
1

Who runs them

Industry 4 · Other 3

MiNK Therapeutics (3) · Memorial Sloan Kettering Cancer Center (1) · University of Wisconsin, Madison (1) · Darren Sigal, MD (1) · ImmunityBio, Inc. (1)

Often tested with

Tested in the same studies.

Botensilimab (2) · Balstilimab (2) · Ramucirumab (1) · Paclitaxel (1) · Nogapendekin alfa inbakicept (1)

Studies

Open first, then newest update. How each study uses Allogeneic Invariant Natural Killer T-cells agenT-797 is read from its arms, and is right about nine times in ten.

Testing it · 7

Given in every arm · 1 — Allogeneic Invariant Natural Killer T-cells agenT-797 is usual care beside what is tested